IRONDisc Medicine, Inc.

Healthcare
$74.55+0.26% 1Y

Price

+0.26%1Y

End-of-day closes, not the intraday tick.

RyuScore

Weak, higher than 8% of companies
10/100
Scroll down to see the criteria

The five questions

2 of 5 available

Only two of the five can be answered for IRON today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.

  • Is the business good?not enough filed
  • Is it safe?Watch
  • Is the price fair?not enough filed
  • Is it growing?not enough filed
  • What is the market doing?Mixed
What they do

We are a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. We have assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.

In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR

P/En/a
Market value$2.86B
1 year+0.26%
5 years-31%

Charts

As reported to the SEC, without any scoring.

The next results filing is expected around Jan 11, 2027, the same week as a year ago.

What the company said

The company's own words from its current reports to the SEC, newest first

  1. Oct 22, 2026On October 20, 2026, Disc Medicine, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC, Leerink Partners LLC, Morgan Stanley & Co. LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters listed on Schedule I thereto (the …Material agreement entered · Form 8-K
  2. Oct 19, 2026Webcast Presentation On October 19, 2026, the Company will host a webcast to discuss topline results from the APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria (“EPP”)Regulation FD disclosure · Form 8-K
  3. Sep 10, 2026On September 9, 2026, the Company announced initial results from the RESTORE-PV clinical trial of DISC-3405 in patients with PV. The Phase 2, multi-center, open-label RESTORE-PV trial enrolled 40 adult participants with PV, including 20 participants in Cohort A and 20 participants in Cohort B. In the trial, following …Regulation FD disclosure · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.

On our screens:Most shorted stocks

Biotechnology

Ranks #108 of 194 by RyuScore

Compare peers
VKTX-5.6%
Viking Therapeutics, Inc.
DYN-1.1%
Dyne Therapeutics, Inc.
DNLI-1.5%
Denali Therapeutics Inc.
NRIX-0.67%
Nurix Therapeutics, Inc.
TARS-5.6%
Tarsus Pharmaceuticals, Inc.
PBLS-8.9%
Parabilis Medicines, Inc.